SCHEMBL2273281

SCHEMBL2273281

O=C(Nc1cc(CCc2ccccc2)ccc1C(=O)O)c1cc(-c2ccccc2)no1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
ALDH1A1 P00352 2/20 0.53
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 2/20 0.47
RAB9A P51151 3/20 0.47
RXFP1 Q9HBX9 1/20 0.47
GFER P55789 1/20 0.44
MAPT P10636 3/20 0.43
NPC1 O15118 2/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
THRB P10828 2/20 0.42
NAMPT P43490 1/20 0.41
ACLY P53396 1/20 0.41
PTPN1 P18031 2/20 0.41
TP53 P04637 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276294 0.86 MEN1 (0.57) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL4215782 0.83 MEN1 (0.42) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL2272461 0.81 SMN1; SMN2 (0.55) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL2270142 0.80 KMT2A (0.52) MEN1KMT2AALDH1A1RAB9ARXFP1
SCHEMBL2271944 0.80 MAPT (0.55) ALDH1A1GFERMAPTTP53
SCHEMBL2275310 0.79 KMO (0.51) MEN1KMT2AALDH1A1SMN1; SMN2RAB9A
SCHEMBL2271421 0.78 DHODH (0.63) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL2277740 0.78 CYP1A2 (0.58) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL2275929 0.78 KMT2A (0.62) MEN1KMT2AMAPTACLY
SCHEMBL2272111 0.76 SUCNR1 (0.59) MEN1KMT2AMAPTACLYHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885ALDH1A1 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.